Top

Published in:

01-01-2022 | Multiple Sclerosis | Original Communication

Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

Authors: Jordi Río, Àlex Rovira, Claudio Gasperini, Mar Tintoré, Luca Prosperini, Susana Otero-Romero, Manuel Comabella, Ángela Vidal-Jordana, Ingrid Galán, Luciana Midaglia, Breogán Rodriguez-Acevedo, Ana Zabalza, Joaquim Castilló, Georgina Arrambide, Carlos Nos, Álvaro Cobo, Carmen Tur, Cristina Auger, Jaume Sastre-Garriga, Xavier Montalban

Published in: Journal of Neurology | Issue 1/2022

Abstract

Background and objectives

Different treatment response scoring systems in treated MS patients exist. The objective was to assess the long-term predictive value of these systems in RRMS patients treated with self-injectable DMTs.

Methods

RRMS-treated patients underwent brain MRI before the onset of therapy and 12 months thereafter, and neurological assessments every 6 months. Clinical and demographic characteristics were collected at baseline. After the first year of treatment, several scoring systems [Rio score (RS), modified Rio score (MRS), MAGNIMS score (MS), and ROAD score (RoS)] were calculated. Cox-Regression and survival analyses were performed to identify scores predicting long-term disability.

Results

We included 319 RRMS patients. Survival analyses showed that patients with RS > 1 and RoS > 3 had a significant risk of reaching an EDSS of 4.0 and 6.0 The score with the best sensitivity (61%) was the RoS, while the MRS showed the best specificity (88%). The RS showed the best positive predictive value (42%) and the best accuracy (81%).

Conclusions

The combined measures integrated into different scores have an acceptable prognostic value for identifying patients with long-term disability.

Thus, these data reinforce the concept of early treatment optimization to minimize the risk of long-term disability.

Rotstein D, Montalban X (2019) Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15(5):287–300CrossRef

Gasperini C, Prosperini L, Tintoré M et al (2019) Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. Neurology 92:180–192CrossRef

Sormani MP, De Stefano N (2013) Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol 9:504–512CrossRef

Río J, Castilló J, Rovira A et al (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 15(7):848–853CrossRef

Sormani M, Signori A, Stromillo M, De Stefano N (2013) Refining response to treatment as defined by the Modified Rio Score. Mult Scler 19(9):1246–1247CrossRef

Sormani MP, Gasperini C, Romeo M et al (2016) Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology 87(2):134–140CrossRef

Gasperini C, Prosperini L, Rovira A et al (2021) Scoring the 10 year risk of ambulatory disability in DMD-treated multiple sclerosis patients: the RoAD score. Eur J Neurol 28(8):2533–2542CrossRef

Bermel RA, You X, Foulds P et al (2013) Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 73:95–103CrossRef

Río J, Rovira A, Tintoré M et al (2018) Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients. Mult Scler 24:322–330CrossRef

10.

Bergamaschi R, Berzuini C, Romani A, Cosi V (2001) Predicting secondary progression in relapsing–remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 189(1–2):13–21CrossRef

11.

Bergamaschi R, Quaglini S, Trojano M et al (2007) Early prediction of the long-term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry 78(7):757–759CrossRef

12.

Bergamaschi R, Montomoli C, Mallucci G et al (2015) BREMSO: a simple score to predict early the natural course of multiple sclerosis. Eur J Neurol 22(6):981–989CrossRef

13.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRef

14.

Wattjes MP, Rovira À, Miller D et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis–establishing disease prognosis and monitoring patients. Nat Rev Neurol 11(10):597–606PubMed

15.

Brown JWL, Coles A, Horakova D et al (2019) Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321(2):175–187CrossRef

16.

Harding K, Williams O, Willis M et al (2019) Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 76(5):536–541CrossRef

17.

Río J, Ruiz-Peña JL (2016) Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci 361:158–167CrossRef

18.

Río J, Comabella M, Montalban X (2009) Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 5(10):553–560CrossRef

19.

Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C (2009) One year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 16(11):1202–1209CrossRef

20.

Prosperini L, Mancinelli C, Haggiag S et al (2020) Minimal evidence of disease activity (MEDA) in relapsing–remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 91:271–277CrossRef

21.

Rae-Grant A, Day GS, Marrie RA et al (2018) Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis neurology. Neurology 90:777–788CrossRef

22.

Rush CA, MacLean HJ, Freedman MS (2015) Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol 11(7):379–389CrossRef

23.

Romeo M, Martinelli V, Rodegher M et al (2015) Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients. Eur J Neurol 22:973–980CrossRef

24.

Rio J, Nos C, Tintoré M et al (2006) Defining the response to interferon-beta in relapsing–remitting multiple sclerosis patients. Ann Neurol 59:344–352CrossRef

25.

Filippi M, Rocca MA (2010) Multiple sclerosis: monitoring long-term treatments in multiple sclerosis. Nat Rev Neurol 6:421–422CrossRef

26.

Alenda R, Costa-Frossard L, Alvarez-Lafuente R et al (2018) Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. J Neurol 265:24–31CrossRef

27.

Tintoré M, Rovira A, Río J et al (2008) Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 70(13 Pt 2):1079–1083CrossRef

28.

Galassi S, Prosperini L, Logoteta A et al (2016) A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta. Mult Scler Relat Disord 8:99–106CrossRef

29.

Iaffaldano P, Lucisano G, Butzkueven H et al (2021) Early treatment delays long-term disability accrual in RRMS: results from the BMSD network. Mult Scler. https://doi.org/10.1177/132458211010/28CrossRefPubMed

30.

Kalincik T, Diouf I, Sharmin S et al (2021) Effect of disease-modifying therapy on disability in relapsing–remitting multiple sclerosis over 15 years. Neurology 96:e783–e797CrossRef

31.

He A, Merkel B, Brown JWL et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19:307–316CrossRef

32.

Buron MD, Chalmer TA, Sellebjerg F et al (2020) Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology 95:e1041–e1051CrossRef

33.

Iaffaldano P, Lucisano G, Caputo F et al (2021) Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord 14:1–10CrossRef

Title: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients
Authors: Jordi Río
Àlex Rovira
Claudio Gasperini
Mar Tintoré
Luca Prosperini
Susana Otero-Romero
Manuel Comabella
Ángela Vidal-Jordana
Ingrid Galán
Luciana Midaglia
Breogán Rodriguez-Acevedo
Ana Zabalza
Joaquim Castilló
Georgina Arrambide
Carlos Nos
Álvaro Cobo
Carmen Tur
Cristina Auger
Jaume Sastre-Garriga
Xavier Montalban
Publication date: 01-01-2022
Publisher: Springer Berlin Heidelberg
Keyword: Multiple Sclerosis
Published in: Journal of Neurology / Issue 1/2022
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-021-10823-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

Abstract

Background and objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

COVID-19 and Parkinson’s disease: a casual association or a possible second hit in neurodegeneration?

Asymmetric rapidly progressive idiopathic normal-pressure hydrocephalus: description of a case

A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: time for more and larger randomized placebo-controlled trials

Parameters for subthalamic deep brain stimulation in patients with dystonia: a systematic review

Music to move persons with Parkinson’s disease: a personalized approach

SARS-CoV-2 infection and acute ischemic stroke in Lombardy, Italy